HBV pgRNA在慢性乙型肝炎感染者治疗中的临床价值

摘要/Abstract

摘要： 由于外周血乙型肝炎病毒(hepatitis B virus,HBV)前基因组RNA(pregenomic RNA,pgRNA)被认为与肝细胞内的共价闭合环状DNA(covalently closed circular DNA, cccDNA)的转录活性有关,因此许多学者致力于研究HBV pgRNA在慢性乙型病毒性肝炎(chronic hepatitis B, CHB)诊疗过程中的应用价值。本综述介绍了pgRNA对CHB病情进展、抗病毒疗效及肝癌根治性手术后复发的预测价值,抗病毒治疗不同时间点的pgRNA水平对停药后复发的影响,以及不同治疗方案对pgRNA水平的影响。但就目前研究现状,对于pgRNA的认识和研究仍处于初级阶段,pgRNA的检测方法及在CHB诊疗过程中的具体应用等方面仍缺乏相关共识,需大量研究进一步明确。

林欣其, 肖丽. HBV pgRNA在慢性乙型肝炎感染者治疗中的临床价值[J]. 肝脏, 2024, 29(2): 240-243.

参考文献

[1] WHO. Hepatitis B[EB/OL].(2023-07-18)[2024-01-01]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
[2] Xia Y, Guo H. Hepatitis B virus cccDNA: formation, regulation and therapeutic potential[J]. Antiviral Res, 2020, 180: 104824.
[3] Shih C, Yang C C, Choijilsuren G, et al. Hepatitis B virus[J]. Trends Microbiol, 2018, 26(4): 386-387.
[4] Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA[J]. PLoS Pathog, 2020, 16(10): e1008945.
[5] 张媛媛, 王莉娟, 徐云芳. 血清HBV pgRNA的特征及临床价值[J]. 临床与病理杂志, 2020, 40(4): 1018-1022.
[6] Luo Y, Cheng J, Hu Z, et al. Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators[J]. Antiviral Res, 2021, 191: 105080.
[7] Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 2017, 66(2): 460-462.
[8] Pan Y, Ke Z, Ye H, et al. Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis[J]. Inflamm Res, 2019, 68(12): 1025-1034.
[9] 陈红, 黄富敏, 琳杰, 等. 慢性HBV感染患者血清pgRNA的表达及意义[J]. 中华医院感染学杂志, 2022, 32(6): 880-884.
[10] Wu Y, Wen J, Xiao W, et al. Pregenomic RNA: how to assist the management of chronic hepatitis B?[J]. Rev Med Virol, 2019, 29(4): e2051.
[11] 彭亚梦, 袁浩, 周毅峰, 等. 低水平乙型肝炎病毒DNA慢性乙型肝炎患者血清乙型肝炎病毒RNA水平及其影响因素研究[J]. 中国全科医学, 2019, 22(18):2217-2222.
[12] 潘美晨, 时景仁, 王爽, 等. HBV pgRNA在HBV相关疾病中的表达及其临床意义[J]. 标记免疫分析与临床, 2019, 26(8): 1269-1272, 1289.
[13] Pan J, Xu J, Luo H, et al. Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy[J]. Int J Infect Dis, 2021, 105: 418-423.
[14] Luo H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues[J]. J Viral Hepat, 2020, 27(3): 323-328.
[15] Wu Y, Wen J, Tang G, et al. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B[J]. J Infect, 2021, 83(5): 594-600.
[16] Tao Y, Wang M, Liao J, et al. Dynamics of serum pregenome RNA in chronic hepatitis B patients receiving 96-month nucleos(t)ide analog therapy[J]. Front Med (Lausanne), 2022, 9: 787770.
[17] 贺金枝, 许艺凡, 雷学忠. 乙型肝炎病毒pgRNA在慢性乙型肝炎患者抗病毒治疗停药抉择中的临床意义[J]. 中华肝脏病杂志, 2022, 30(9): 970-975.
[18] Jiang B, Dai Q, Liu Y, et al. Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy[J]. Infect Agent Cancer, 2022, 17(1): 61.
[19] 于彤波, 付伦, 赵汉东, 等. 血清HBV pgRNA在核苷类似物治疗CHB患者中的临床价值[J]. 检验医学与临床, 2022, 19(21): 2881-2884.
[20] Wu W, Wu D, Yan W, et al. Interferon-induced macrophage-derived exosomes mediate antiviral activity against hepatitis B virus through miR-574-5p[J]. J Infect Dis, 2021, 223(4): 686-698.
[21] Imam H, Kim G W, Mir S A, et al. Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified hepatitis B virus transcripts[J]. PLoS Pathog, 2020, 16(2): e1008338.
[22] Gan W, Chen X, Wu Z, et al. The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment[J]. Ann Transl Med, 2022, 10(10): 536.
[23] 刘忠伟, 刘明, 龚红梅, 等. 血清pgRNA对聚乙二醇干扰素治疗低HBeAg水平慢性乙型肝炎患者HBeAg清除的预测意义[J]. 陆军军医大学学报, 2022, 44(2): 155-161.
[24] Limothai U, Chuaypen N, Poovorawan K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(12): 1481-1488.
[25] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303.
[26] 夏晓露, 肖玉玲, 邱培, 等. 肝癌根治性切除术后复发的高危因素分析[J]. 实用癌症杂志, 2020, 35(11): 1875-1878.
[27] Zhang H, Han J, Xing H, et al. Sex difference in recurrence and survival after liver resection for hepatocellular carcinoma: a multicenter study[J]. Surgery, 2019, 165(3): 516-524.
[28] Ding W B, Wang M C, Yu J, et al. HBV/Pregenomic RNA increases the stemness and promotes the development of HBV-related HCC through reciprocal regulation with insulin-like growth factor 2 mRNA-binding protein 3[J]. Hepatology, 2021, 74(3): 1480-1495.
[29] Mak L Y, Huang Q, Wong D K, et al. Residual HBV-DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy[J]. J Gastroenterol, 2021, 56(5): 479-488.
[30] Wong G L H, Gane E, Lok A S F. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?[J]. J Hepatol, 2022, 76(6): 1249-1262.
[31] Zhang Q L, Vendeville S, Serebryany V, et al. ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B[C]. Journal of Hepatology, 2020 73: S880-S881.
[32] Mukherjee S, Zhang Q L, Misner D, et al. The prodrug of a novel capsid assembly modulator (CAM), ALG-000184, demonstrates a favorable nonclinical toxicokinetic and toxicology profile for the treatment of chronic hepatitis B (CHB)[C]. International Journal of Toxicology, 2023, 42(1): 93-94.
[33] Yuen M F, Agarwal K, Gane E J, et al. Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B[C]. Journal of Hepatology, 2022, 77: S835-S836.
[34] Zhang D, Wu W Q, Chwn S K, et al. GST-HG141 inhibits de novo HBV cccDNA formation in cultured primary human hepatocytes[C]. Journal of Hepatology, 2022, 77: S748-S749.
[35] Mai J J, Zhang H, Wu M, et al. Safety, pharmacokinetics and antiviral activity of GST-HG141, a hepatitis B virus capsid assembly modulator, in subjects with chronic hepatitis B[C]. Journal of Hepatology, 2022, 77: S865.
[36] Zhang D, Wu W Q, Chen S K, et al. GST-HG141, a novel clinical-stage hepatitis B virus capsid assembly modulator[C]. Journal of Hepatology, 2021, 75: S748-S749.
[37] Feld J, Lawitz E, Nguyen T T, et al. EDP-514, a novel pangenotypic class Ⅱ hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients[C]. Journal of Hepatology, 2022, 77: S848.
[38] Yuen M F, Chuang W L, Peng C Y, et al. EDP-514, a potent pangenotypic class Ⅱ hepatitis B virus core inhibitor, demonstrates significant HBV-DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B Patients[C]. Journal of Hepatology, 2022, 77: S849.
[39] Feld J, Lawitz E, Nguyen T, et al. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B[J]. Antiviral Therapy, 2022, 26(6):13596535221127848.
[40] Vandenbossche J, Jessner W, van den Boer M, et al. Correction to: pharmacokinetics, safety and tolerability of JNJ-56136379, a novel hepatitis B virus capsid assembly modulator, in healthy subjects[J]. Adv Ther, 2020, 37(4): 1703.
[41] Berke J M, Dehertogh P, Vergauwen K, et al. Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379[J]. Antimicrob Agents Chemother, 2020, 64(5): e02439-19.
[42] Zoulim F, Lenz O, Vandenbossche J J, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection[J]. Gastroenterology, 2020, 159(2): 521-533.e9.
[43] Verbineen T, Hodari M, Talloen W, et al. Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy[J]. J Viral Hepat, 2020, 27(11): 1127-1137.
[44] Gane E, Jucov A, Kolomiichuk L, et al. Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)[C]. J Hepatol, 2022, 77: S848-S849.
[45] Mani N, Cole A G, Kultgen S G, et al. Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor[C]. J Hepatol, 2021, 75: S281.